What Opus Genetics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 2 |
| Sells | 2 | 18 |
| Total trades | 5 | 46 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 1,176,471 | 3,749,644 |
| Disposed | 659,541 | 6,505,270 |
| Net activity | +516,930 | −2,755,626 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Foundation Fighting Blindness Retinal Degeneration Fund | Director | Sep 30 | Open-market sale · S | −556,000 | $4.96 | −$2.76M | 3,236,171 |
| Magrath George | Chief Executive Officer | Sep 09 | Withheld — tax / exercise cost · F | −75,541 | $5.97 | −$451K | 2,048,485 |
| Magrath George | Chief Executive Officer | Sep 09 | Exercise / conversion · M | +392,157 | $1.15 | +$451K | 2,124,026 |
| Gallagher Cam | Director | Sep 08 | Exercise / conversion · M | +784,314 | $1.15 | +$902K | 2,800,111 |
| Gagnon Robert E. | Chief Financial Officer | Sep 03 | Open-market sale · S | −28,000 | $4.54 | −$127K | 556,375 |
| Magrath George | Chief Executive Officer | Jul 23 | Open-market sale · S | −9,475 | $2.95 | −$27.9K | 1,731,869 |
| Gagnon Robert E. | Chief Financial Officer | Jul 23 | Open-market sale · S | −7,783 | $2.95 | −$22.9K | 584,375 |
| Yerxa Benjamin R | President | Jul 23 | Open-market sale · S | −7,429 | $2.97 | −$22.1K | 704,106 |
| Schachle Joseph K | Chief Operating Officer | Jul 23 | Open-market sale · S | −4,644 | $2.94 | −$13.7K | 291,440 |
| Foundation Fighting Blindness Retinal Degeneration Fund | Director | May 18 | Open-market sale · S | −1,700,000 | $4.35 | −$7.4M | 3,792,171 |
| Schachle Joseph K | Chief Operating Officer | Apr 23 | Open-market sale · S | −4,697 | $5.22 | −$24.5K | 296,084 |
| Gagnon Robert E. | Chief Financial Officer | Apr 23 | Open-market sale · S | −7,842 | $5.18 | −$40.7K | 592,158 |
| Jayagopal Ashwath | Chief Scientific & Dev. Ofc. | Apr 23 | Open-market sale · S | −7,542 | $5.19 | −$39.2K | 509,233 |
| Magrath George | Chief Executive Officer | Apr 23 | Open-market sale · S | −9,511 | $5.22 | −$49.6K | 1,741,344 |
| Zaremba Rabourn Amy | Head of Fin. Quality Assurance | Apr 23 | Open-market sale · S | −1,641 | $5.20 | −$8.54K | 188,671 |
| Yerxa Benjamin R | President | Apr 23 | Open-market sale · S | −7,470 | $5.24 | −$39.1K | 711,535 |
| Bennett Jean | Director | Apr 20 | Grant / award · A | +24,367 | — | — | 259,019 |
| Graves Adrienne L | Director | Apr 20 | Grant / award · A | +24,367 | — | — | 127,514 |
| Rodgers Richard J | Director | Apr 20 | Grant / award · A | +24,367 | — | — | 343,022 |
| Ainsworth Sean | Director | Apr 20 | Grant / award · A | +24,367 | — | — | 321,692 |
Loading...
